Serum CEA Level Change and Its Significance Before and after Gefitinib Therapy on Patients with Advanced Non-small Cell Lung Cancer

被引:20
作者
Qin, Hai-Feng [1 ]
Qu, Li-Li [1 ]
Liu, Hui [1 ]
Wang, Sha-Sha [1 ]
Gao, Hong-Jun [1 ]
机构
[1] Acad Mil Med Sci, Affiliated Hosp, Dept Pulm Neoplasms Internal Med, Beijing, Peoples R China
关键词
Non-small-cell lung cancer; advanced; gefitinib; carcino-embryonic antigen; EGFR T790M MUTATION; GROWTH-FACTOR; PROGNOSTIC-FACTORS; ERLOTINIB; RESISTANCE; CHEMOTHERAPY; MECHANISMS; INHIBITOR;
D O I
10.7314/APJCP.2013.14.7.4205
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: The aim of this study was to explore change and significance of serum carcino-embryonic antigen (CEA) before and after gefitinib therapy in patients with advanced non-small-cell lung cancer (NSCLC). Methods: Forty patients with advanced NSCLCs in III similar to IV stages were selected as study objects given gefitinib therapy combined with routine local radiotherapy until tumor progression or intolerable toxicity. After treatment, all patients were divided into control and non-control groups according to the results of evaluation based on RECIST 1.1 (Response Evaluation Criteria in Solid Tumors in 2009). Peripheral fasting blood from all patients was collected in the early morning and serum CEA was assessed by electro-chemiluminescence immunoassay (ECLIA) before and after treatment. Before treatment, patients were divided into high CEA group (CEA level > 50 ng/mL) and low CEA group (CEA level <= 50 ng/mL). Adverse reactions were noted and progression-free survival (PFS) in both groups was recorded after long-term follow-up that ended in December, 2012. Results: There was no difference between control and non-control groups in CEA level before treatment (P>0.05), whereas serum CEA decreased more markedly lower in the control group after treatment (P<0.01). All patients were divided into high CEA group (26) and low CEA group (14) according to serum CEA level. There was no statistically significant difference between two groups in adverse reactions (P>0.05) but the rate in former group was lower. Additionally, survival rates at 9 and 12 months in high CEA group were clearly higher than in the low CEA group (P<0.01). Conclusions: Serum CEA level can serve as a biochemical index to evaluate the prognosis with gefitinib treatment for NSCLC.
引用
收藏
页码:4205 / 4208
页数:4
相关论文
共 26 条
[1]   Cross-talk between MET and EGFR in non-small cell lung cancer involves miR-27a and Sprouty2 [J].
Acunzo, Mario ;
Romano, Giulia ;
Palmieri, Dario ;
Lagana, Alessandro ;
Garofalo, Michela ;
Balatti, Veronica ;
Drusco, Alessandra ;
Chiariello, Mario ;
Nana-Sinkam, Patrick ;
Croce, Carlo M. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2013, 110 (21) :8573-8578
[2]  
Al Dayel Fouad, 2012, J Infect Public Health, V5 Suppl 1, pS31, DOI 10.1016/j.jiph.2012.09.008
[3]   Concomitant overexpression of EGFR and CXCR4 is associated with worse prognosis in a new molecular subtype of non-small cell lung cancer [J].
Al Zobair, Alya A. ;
Al Obeidy, Barrak F. ;
Yang, Lei ;
Yang, Chunxu ;
Hui, Yang ;
Yu, Haltun ;
Zheng, Fang ;
Yang, Guifang ;
Xie, Conghua ;
Zhou, Fuxiang ;
Zhou, Yunfeng .
ONCOLOGY REPORTS, 2013, 29 (04) :1524-1532
[4]   Review of the Treatment of Non-Small Cell Lung Cancer with Gefitinib [J].
Araki, Takuya ;
Yashima, Hideaki ;
Shimizu, Kimihiro ;
Aomori, Tohru ;
Hashita, Tadahiro ;
Kaira, Kyoichi ;
Nakamura, Tomonori ;
Yamamoto, Koujirou .
CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2012, 6
[5]   Clinical Outcomes and Prognostic Factors Associated with the Response to Erlotinib in Non-Small-Cell Lung Cancer Patients with Unknown EGFR Mutational Status [J].
Aydiner, Adnan ;
Yildiz, Ibrahim ;
Seyidova, Avesta .
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2013, 14 (05) :3255-3261
[6]   Effect of siRNAs targeting the EGFR T790M mutation in a non-small cell lung cancer cell line resistant to EGFR tyrosine kinase inhibitors and combination with various agents [J].
Chen, Gang ;
Kronenberger, Peter ;
Teugels, Erik ;
Umelo, Ijeoma Adaku ;
De Greve, Jacques .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2013, 431 (03) :623-629
[7]   mRNA Expression and Clinical Significance of ERCC1, BRCA1, RRM1, TYMS and TUBB3 in Postoperative Patients with Non-Small Cell Lung Cancer [J].
Han, Yi ;
Wang, Xiao-Bin ;
Xiao, Ning ;
Liu, Zhi-Dong .
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2013, 14 (05) :2987-2990
[8]  
Jeon WI, 2012, ANTICANCER RES, V32, P5279
[9]   BRCA1, LMO4, and CtIP mRNA Expression in Erlotinib-Treated Non-Small-Cell Lung Cancer Patients with EGFR Mutations [J].
Karachaliou, Niki ;
Costa, Carlota ;
Gimenez-Capitan, Ana ;
Angel Molina-Vila, Miguel ;
Bertran-Alamillo, Jordi ;
Mayo, Clara ;
Massuti, Bartomeu ;
Majem, Margarita ;
Carcereny, Enric ;
Moran, Teresa ;
Javier Sanchez, Jose ;
Viteri, Santiago ;
Gasco, Amaya ;
Wannesson, Luciano ;
Souglakos, John ;
Jimeno, Jose ;
Rosell, Rafael .
JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (03) :295-300
[10]   Erlotinib Versus Gefitinib for Control of Leptomeningeal Carcinomatosis in Non-Small-Cell Lung Cancer [J].
Lee, Eunyoung ;
Keam, Bhumsuk ;
Kim, Dong-Wan ;
Kim, Tae Min ;
Lee, Se-Hoon ;
Chung, Doo Hyun ;
Heo, Dae Seog .
JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (08) :1069-1074